Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Analysts at SVB Leerink cut their Q2 2022 earnings per share estimates for Axsome Therapeutics in a research note issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will post earnings of ($1.09) per share for the quarter, down from their prior estimate of ($1.05). SVB Leerink has a “Outperform” rating and a $50.00 price objective on the stock. SVB Leerink also issued estimates for Axsome Therapeutics’ Q3 2022 earnings at ($1.07) EPS, Q4 2022 earnings at ($1.25) EPS, FY2022 earnings at ($4.25) EPS and FY2023 earnings at ($5.50) EPS.
A number of other equities analysts also recently weighed in on AXSM. StockNews.com initiated coverage on shares of Axsome Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research downgraded shares of Axsome Therapeutics from a “buy” rating to a “hold” rating and set a $32.00 target price for the company. in a research note on Friday, March 4th. Finally, Jefferies Financial Group lifted their target price on shares of Axsome Therapeutics from $71.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $80.78.
Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last announced its earnings results on Tuesday, March 1st. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.09. During the same quarter in the prior year, the company posted ($0.78) EPS.
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of Axsome Therapeutics by 2.0% during the fourth quarter. BlackRock Inc. now owns 2,109,622 shares of the company’s stock worth $79,700,000 after acquiring an additional 41,559 shares in the last quarter. Bellevue Group AG increased its position in shares of Axsome Therapeutics by 113.9% during the third quarter. Bellevue Group AG now owns 752,945 shares of the company’s stock worth $24,817,000 after acquiring an additional 400,924 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 507,485 shares of the company’s stock worth $19,172,000 after acquiring an additional 16,055 shares in the last quarter. Nuveen Asset Management LLC increased its position in shares of Axsome Therapeutics by 55.3% during the fourth quarter. Nuveen Asset Management LLC now owns 494,206 shares of the company’s stock worth $18,671,000 after acquiring an additional 175,949 shares in the last quarter. Finally, Morgan Stanley increased its position in shares of Axsome Therapeutics by 15.3% during the third quarter. Morgan Stanley now owns 365,969 shares of the company’s stock worth $12,062,000 after acquiring an additional 48,523 shares in the last quarter. 48.45% of the stock is owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile (Get Rating)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.